| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
LRE1 targets soluble adenylyl cyclase (sAC), a ubiquitously expressed enzyme that is an essential component of cAMP signaling. Unlike G-protein-regulated transmembrane adenylyl cyclases, sAC is directly activated by calcium and bicarbonate and is dispersed throughout the cytoplasm. LRE1 binds to the bicarbonate activator binding site, inhibiting sAC activity through an allosteric mechanism.
|
|---|---|
| ln Vitro |
Through a distinct allosteric mechanism, LRE1 binds to the bicarbonate activator binding site and inhibits soluble adenylyl cyclase (sAC) [1]. By blocking sAC-dependent activities in physiological and cellular systems, LRE1 (0.5-100 μM, 60 min) makes it easier to explore the functions of sAC in the septum and Manchester [1].
LRE1 inhibits cAMP accumulation in 4-4 cells with an IC50 of 11 μM. It inhibits sAC-dependent activities in physiological and cellular systems. The compound has an IC50 of ≤10 μM for sAC inhibition. It shows similar potency to KH7 but without cellular toxicity. |
| ln Vivo |
In vivo activity data for LRE1 are limited in the available literature. The compound is used to study sAC function in physiological systems. By blocking sAC-dependent activities, it facilitates exploration of sAC function in various tissues. In vivo studies would be required to assess therapeutic potential.
|
| Enzyme Assay |
Non-cell-based enzyme assays for LRE1 use purified soluble adenylyl cyclase (sAC) enzyme. The compound is incubated with the enzyme, ATP substrate, and activators (bicarbonate and/or calcium) at varying concentrations. sAC activity is measured by quantifying cAMP production using radioimmunoassay, ELISA, or mass spectrometry. IC50 values for enzyme inhibition are determined.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: Mouse Tail Sperm Tested Concentrations: 0.5-100 μM Incubation Duration: 60 minutes Experimental Results: LRE1 inhibits sAC-dependent sperm capacitation [1]. Cellular assays for LRE1 utilize 4-4 cells or other sAC-expressing cell lines. Cells are treated with the compound at various concentrations (0.5-100 μM). cAMP accumulation is measured following stimulation with bicarbonate or other sAC activators. IC50 values for inhibition of cAMP accumulation are determined. |
| Animal Protocol |
In vivo animal models for LRE1 would be required to assess its therapeutic potential. The compound is used to study sAC function in physiological systems. By blocking sAC-dependent activities, it facilitates exploration of sAC function in various tissues including the septum and other organs. Detailed protocols are not extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of LRE1 include CAS number 1252362-53-0. The compound is a small molecule sAC inhibitor. Detailed PK parameters such as half-life and bioavailability are not extensively reported. The compound is a research tool for studying sAC biology.
|
| Toxicity/Toxicokinetics |
LRE1 shows similar potency to KH7 but without cellular toxicity. This suggests a more favorable safety profile compared to other sAC inhibitors. Detailed toxicity data are not extensively reported. The compound is a research tool for studying sAC function. It has potential therapeutic applications where sAC inhibition is beneficial.
|
| References | |
| Additional Infomation |
LRE1 is also known as RU-0204277. It has CAS number 1252362-53-0. The compound is a specific and allosteric inhibitor of soluble adenylyl cyclase (sAC). It binds to the bicarbonate activator binding site. It inhibits cAMP accumulation with an IC50 of 11 μM. It is a research tool for sAC biology.
|
| Molecular Formula |
C12H13CLN4S
|
|---|---|
| Molecular Weight |
280.776419401169
|
| Exact Mass |
280.05
|
| Elemental Analysis |
C, 51.33; H, 4.67; Cl, 12.63; N, 19.95; S, 11.42
|
| CAS # |
1252362-53-0
|
| Related CAS # |
1252362-53-0;
|
| PubChem CID |
47279808
|
| Appearance |
White to off-white solid powder
|
| LogP |
3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
289
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC1N(CC2=CC=CS2)C3=CC(=NC(=N3)N)Cl
|
| InChi Key |
PDWZXKSZLRVSEH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H13ClN4S/c13-10-6-11(16-12(14)15-10)17(8-3-4-8)7-9-2-1-5-18-9/h1-2,5-6,8H,3-4,7H2,(H2,14,15,16)
|
| Chemical Name |
6-chloro-4-N-cyclopropyl-4-N-(thiophen-2-ylmethyl)pyrimidine-2,4-diamine
|
| Synonyms |
LRE1, T15787; T-15787; T 15787;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~445.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5615 mL | 17.8075 mL | 35.6151 mL | |
| 5 mM | 0.7123 mL | 3.5615 mL | 7.1230 mL | |
| 10 mM | 0.3562 mL | 1.7808 mL | 3.5615 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
